Prof. Jiguang Han 韩继广
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of benign and malignant breast tumors. Expertise includes breast-conserving surgery, sentinel lymph node biopsy, mastectomy with immediate reconstruction (implant or flap), and Mammotome minimally invasive procedures for benign tumors and stereotactic biopsy of calcifications.
Dr. Han graduated from Harbin Medical University in 2002 and holds master’s and doctoral degrees. As a Chief Physician and Associate Professor, Dr. Han performs various breast cancer surgeries, including endoscopic and robotic-assisted procedures for reconstruction or breast-conserving surgery to improve cosmetic outcomes. The medical team also conducts Mammotome minimally invasive surgeries for benign breast tumors.
Professional roles
- Member, Breast Cancer Committee, Chinese Medical Association
- Member, Breast Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO-BC)
- Member, Breast Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Youth Committee Member, Breast Cancer Professional Committee, Chinese Medical Association
Name order: in Chinese the family name comes first (Han Jiguang). Papers usually list the name as Jiguang Han or Han J.
Selected publications
17 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2026 (senior author): Interpretable machine learning model for brain metastasis in breast cancer: a large-scale, multi-center study. PubMed 42902382
- Transl Cancer Res, 2026 (senior author): Mitochondrial gene APOO reprograms lipid metabolism to influence the prognosis of breast cancer. PubMed 42180875
- Ther Adv Drug Saf, 2025 (senior author): Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration Adverse Event Reporting System and Canada Vigilance Adverse Reaction Online Database. PubMed 41409394
- Front Immunol, 2025 (senior author): Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma In Situ post-lumpectomy. PubMed 41030436
- Toxicol Appl Pharmacol, 2018 (first author): Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. PubMed 30244121
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion